NetScientific notes that its portfolio company, Vortex Technology, has announced a report published by Nature Scientific Reports.
London, UK – 09 February 2018 – NetScientific plc (“NetScientific”, AIM:NSCI), the transatlantic healthcare IP commercialisation group, notes that its portfolio company, Vortex Technology, has announced a report published by Nature Scientific Reports. The peer reviewed report, titled “Evaluation of PD-L1 expression on vortex-isolated circulating tumor cells in metastatic lung cancer” describes the use of the Vortex’s technology in capturing circulating tumour cells (CTCs), in combination with the use of a novel immunofluorescence assay, for measuring programmed cell death ligand 1 (PD-L1) expression on the surface of the CTCs from patients with metastatic non-small cell lung cancer (NSCLC).
The report can be found online here: https://www.nature.com/articles/s41598-018-19245-w
Commenting on the news, Francois Martelet, Chairman of Vortex BioSciences Inc. and CEO of NetScientific said: “This report demonstrates the potential clinical utility of circulating tumour cells captured by the Vortex technology in the treatment of lung cancer patients. Recent clinical trials of PD-1 and PD-L1 inhibitors have returned promising clinical responses, providing a rationale for use of the VTX 1 system in personalised medicine.”
